Pfizer Inc. rea-ffirmed earnings guidance for the Full-Year 2024. For the year, the company expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty and Paxlovid (approximately $5 billion and $3 billion, respectively), approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer?s royalty income from Other (Income)/Deductions into the Revenue line.